KRAS and esophagitis: Cetuximab, in contrast, was an independent predictor for significantly higher toxicity for both non-variant and KRAS-variant patients (Table 4, OR = 3.42, CI: 1.76–6.67, P = 0.0003), but was not specific to hematologic, pulmonary, or esophagitis.